Eczema (Atopic Dermatitis) Clinical Trials in Austin
View 29 new treatments for Eczema (Atopic Dermatitis) in Austin, TX, and nearby areas, such as Round Rock. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Nemolizumab for Eczema
Galderma Clinic, Dripping Springs + 2 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, Pflugerville + 1 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Pfizer CT.gov Call Center
Study Director
Lebrikizumab for Eczema
Eli Lilly Clinic, Pflugerville + 2 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Cedar Park + 1 more
This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
MD
Study Director
Upadacitinib for Eczema
AbbVie Clinic, Austin + 1 more
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide. The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Austin + 1 more
This trial tests a new drug called rocatinlimab combined with common skin treatments on patients with eczema. The goal is to see if this combination works better than standard treatments alone by calming the immune system to reduce symptoms like redness and itching.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
MD
Study Director
Ruxolitinib Cream for Prurigo Nodularis
Incyte Clinic, Austin + 1 more
This trial tests the safety and tolerability of a cream for people with Prurigo Nodularis, a condition with itchy skin nodules. The cream works by blocking enzymes that cause inflammation and itching. It has been previously tested for its effects in conditions like atopic dermatitis.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Eczema
AbbVie Clinic, Pflugerville + 1 more
This trial is testing upadacitinib, an oral medication, to see if it can help people with severe eczema. The medication works by calming down the overactive immune system to reduce skin inflammation and itching. Upadacitinib is approved in many countries for the treatment of atopic dermatitis in individuals whose disease is not adequately controlled with other treatments or when those treatments are not suitable.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
ABBVIE INC.
Study Director
Tapinarof Cream for Eczema
Dermavant Sciences Clinic, Dripping Springs + 1 more
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Diana Villalobos
Study Director
Rocatinlimab for Atopic Dermatitis/Eczema
Amgen Clinic, Cedar Park + 2 more
This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
MD
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions